These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17675819)

  • 1. [Natural history of inflammatory bowel disease].
    Matsui T
    Nihon Shokakibyo Gakkai Zasshi; 2007 Aug; 104(8):1172-82. PubMed ID: 17675819
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword.
    Magro F
    BioDrugs; 2010 Dec; 24 Suppl 1():1-2. PubMed ID: 21175227
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use.
    Tiemi J; Komati S; Sdepanian VL
    J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):628-33. PubMed ID: 20386321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
    Wittig BM; Zeitz M
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S52-8. PubMed ID: 11450615
    [No Abstract]   [Full Text] [Related]  

  • 6. Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal.
    Regadas FS; Pinto RA; Murad-Regadas SM; Canedo JA; Leal M; Nogueras JJ; Wexner SD
    Colorectal Dis; 2011 May; 13(5):555-60. PubMed ID: 20070344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changing treatment of inflammatory bowel diseases].
    Karvonen AL; Matikainen M; Turunen U
    Duodecim; 1994; 110(20):1945-54. PubMed ID: 7555809
    [No Abstract]   [Full Text] [Related]  

  • 8. Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?
    Burakoff R
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S202-3. PubMed ID: 18816760
    [No Abstract]   [Full Text] [Related]  

  • 9. [Inflammatory bowel disease: should all patients be premedicated when infliximab is administered to reduce infusion reactions and/or immunogenicity?].
    Ginard D; Mariño Z
    Gastroenterol Hepatol; 2008 Oct; 31(8):542-3. PubMed ID: 18928758
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current status of treatment of inflammatory bowel disease].
    Rodríguez-Moranta F; Soriano-Izquierdo A; Guardiola J
    Cir Esp; 2007 Nov; 82(5):254-9. PubMed ID: 18021623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs to treat Crohn's disease.
    van Assche G
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):49-59. PubMed ID: 17355213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologicals first-line in chronic inflammatory bowel disease? Yes].
    Stallmach A
    Dtsch Med Wochenschr; 2011 Sep; 136(36):1788. PubMed ID: 21882134
    [No Abstract]   [Full Text] [Related]  

  • 13. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
    Lichtenstein GR; Abreu MT; Cohen R; Tremaine W;
    Gastroenterology; 2006 Mar; 130(3):935-9. PubMed ID: 16530531
    [No Abstract]   [Full Text] [Related]  

  • 14. Crohn disease or intestinal fistulising tuberculosis? Diagnosis difficulties in a case treated with infliximab and corticosteroids.
    Cazacu S; Vere CC; Comănescu V; Dumitrescu C; Enache SD; Ciurea T
    Rom J Morphol Embryol; 2009; 50(2):263-8. PubMed ID: 19434321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
    Lichtenstein GR; Sbreu MT; Cohen R; Tremaine W
    Rev Gastroenterol Mex; 2006; 71(3):351-401. PubMed ID: 17140062
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
    Shen H; Lipka S; Katz S
    J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
    [No Abstract]   [Full Text] [Related]  

  • 17. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
    Lichtenstein GR; Abreu MT; Cohen R; Tremaine W;
    Gastroenterology; 2006 Mar; 130(3):940-87. PubMed ID: 16530532
    [No Abstract]   [Full Text] [Related]  

  • 18. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
    Molnár T
    Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab safety profile and long-term applicability in inflammatory bowel disease: clinical experiences from the eastern side of Europe.
    Molnár T; Farkas K; Nagy F; Szepes Z; Wittmann T
    Aliment Pharmacol Ther; 2010 May; 31(10):1152-3. PubMed ID: 20518754
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease.
    Rednic S; Marinescu C; Chira R; Rogojan L; Rednic N
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):379-82. PubMed ID: 17205151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.